secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-10-14T10:35:34+00:00
Accession:  0001104659-26-115709
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Quoin's QRX003 wins EMA Orphan Drug Designation for Peeling Skin Syndrome
-------------------------------------------------------------------------

- EMA granted Orphan Drug Designation to lead candidate QRX003 for Peeling Skin Syndrome on Oct 14, 2026, giving 10 years of EU market exclusivity if approved.
- Quoin says it is on track to initiate the first-ever formal clinical study in Peeling Skin Syndrome before year end.
- Designation is the eighth regulatory milestone for QRX003, which also holds US FDA Pediatric Rare Disease and Fast Track designations for the indication.
- QRX003 also has Orphan Drug Designation in the US, Europe and Japan for Netherton Syndrome, where it is in late-stage trials and no therapies are approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926115709/0001104659-26-115709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926115709/tm2627548d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-115709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer